Home›Research›Compare›Cagrilintide vs Semaglutide
Peptide ComparisonCagrilintide vs Semaglutide
Both are Metabolic peptides.
Cagrilintide
AM833
Half-life: ~7 days
21 providers listed
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Semaglutide is FDA-approved, while Cagrilintide is investigational — the clearest structural difference between them.
Cagrilintide
Half-life
~7 days
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Further along in FDA review | Semaglutide |
| Less frequent dosing (longer half-life) | Semaglutide |
| Oral administration option | Semaglutide |
| More provider options (21 vs 806) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Cagrilintide
Semaglutide
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Cagrilintide
Semaglutide
Where to source these peptides
Cagrilintide
21 listed
Browse directory →
Providers offeringSemaglutide
806 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Semaglutide — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/semaglutide